| Trial ID: | L0138 |
| Source ID: | NCT02285205
|
| Associated Drug: |
Lobeglitazone
|
| Title: |
A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Type 2 Diabetes|Non-alcoholic Fatty Liver Disease
|
| Interventions: |
Drug: Oral administration of Lobeglitazone
|
| Outcome Measures: |
changes from baseline in controlled attenuation parameters (CAP)
|
| Sponsor/Collaborators: |
Yonsei University
|
| Gender: |
All
|
| Age: |
20 Years and older ?? (Adult, Older Adult)
|
| Phases: |
Phase 4
|
| Enrollment: |
38
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
|
| Start Date: |
November 2014
|
| Completion Date: |
November 2015
|
| Results First Posted: |
--
|
| Last Update Posted: |
February 2, 2016
|
| Locations: |
Severance Hospital, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
|
| URL: |
https://ClinicalTrials.gov/show/NCT02285205
|
